Literature DB >> 25732813

Primary cutaneous cribriform carcinoma: report of six cases with clinicopathologic data and immunohistochemical profile.

David P Arps1, May P Chan1,2, Rajiv M Patel1,2, Aleodor A Andea1,2.   

Abstract

BACKGROUND: Primary cutaneous cribriform carcinoma (PCCC) is a rare and under-recognized variant of sweat gland carcinoma, characterized by anastomosing tubules and solid nests producing a sieve-like appearance.
METHODS: Six cases of PCCC were clinically, histopathologically and immunophenotypically studied.
RESULTS: All cases showed an unencapsulated, nodular dermal tumor composed of solid and cribriform nests, cords and tubules embedded within a desmoplastic stroma. Some tubules showed micropapillary projections reminiscent of tubular adenoma, and intraluminal thin bridges resembling adenomatoid tumor. One case showed a predominantly solid component. Only two cases showed very focal decapitation secretion. Tumor cells expressed CK7, CK5/6, EMA, CEA, S-100, BerEP4 and c-kit and were negative for cytokeratin 20, estrogen receptor/progesterone receptor (ER/PR), androgen receptor and GCDFP-15. Calponin, p63 and smooth muscle actin (SMA) showed absence of a myoepithelial layer.
CONCLUSIONS: Contrary to the original reports, our series shows that PCCC may be predominantly solid with only a minor cribriform component, and expresses c-kit and S-100 which may potentially lead to the misdiagnosis of adenoid cystic carcinoma. Immunohistochemical stains may aid in distinction from tubular adenoma. Current data suggest a favorable outcome, as metastatic disease has not been reported to date.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adenoid cystic carcinoma; adenomatoid; adnexal; cribriform; papillary eccrine adenoma; tubular adenoma

Mesh:

Substances:

Year:  2015        PMID: 25732813     DOI: 10.1111/cup.12469

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  8 in total

1.  [Primary cutaneous cribriform apocrine carcinoma : An underdiagnosed entity?].

Authors:  A Udvardi; B Mayer; B Volc-Platzer; A Rütten
Journal:  Hautarzt       Date:  2016-09       Impact factor: 0.751

2.  Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature.

Authors:  Carlos N Prieto-Granada; Lei Zhang; Cristina R Antonescu; Jean M Henneberry; Jane L Messina
Journal:  J Cutan Pathol       Date:  2016-12-02       Impact factor: 1.587

Review 3.  Reappraisal and literature review of primary cutaneous cribriform apocrine carcinoma.

Authors:  Anna Davis; Amor Khachemoune
Journal:  Arch Dermatol Res       Date:  2022-02-06       Impact factor: 3.017

4.  Two Different Cell Populations Is an Important Clue for Diagnosis of Primary Cutaneous Adenoid Cystic Carcinoma: Immunohistochemical Study.

Authors:  Banu Ince Alkan; Onder Bozdogan; Müjde Karadeniz; Nazan Bozdoğan
Journal:  Case Rep Pathol       Date:  2017-01-24

Review 5.  An Updated Review of Cribriform Carcinomas with Emphasis on Histopathological Diagnosis and Prognostic Significance.

Authors:  Giovanni Branca; Antonio Ieni; Valeria Barresi; Giovanni Tuccari; Rosario Alberto Caruso
Journal:  Oncol Rev       Date:  2017-03-10

6.  Tumor with slow-developing and recurring lumps of the external ear with skull base and lung metastasis: A case report.

Authors:  Zhifang Zhai; Jie Hu; Yi You; Xichuan Yang; Zhiqiang Song
Journal:  Oncol Lett       Date:  2020-06-11       Impact factor: 2.967

7.  Primary Cutaneous Cribriform Apocrine Carcinoma.

Authors:  Michelle Boettler; Martha A Hickmann; Jeffrey B Travers
Journal:  Am J Case Rep       Date:  2021-01-02

Review 8.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.